Literature DB >> 8091904

Immunocytochemical differentiation of reactive mesothelial cells and adenocarcinoma cells in serous effusions with the use of carcinoembryonic antigen and fibronectin.

P Athanassiadou1, P Athanassiades, D Lazaris, K Kyrkou, E Petrakakou, D Aravantinos.   

Abstract

Ninety effusions from patients with breast and ovarian cancer were studied cytologically and classified as benign, suspicious or malignant, and the same samples were studied for carcinoembryonic antigen (CEA) and fibronectin (F) immunostaining. The combination F positive/CEA negative was found to have 100% specificity and 92.3% sensitivity in patients with benign or reactive effusions, and F negative/CEA positive 85.7% specificity and 80.7% sensitivity for malignancy. Immunostaining provides valuable supplementary information in cytologically suspicious patients. In the presence of F negative/CEA negative effusions, it is probable that insufficient cellular material is present for either a cytologic or immunostaining diagnosis.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 8091904

Source DB:  PubMed          Journal:  Acta Cytol        ISSN: 0001-5547            Impact factor:   2.319


  3 in total

1.  Deregulated expression of the human tumor marker CEA and CEA family member CEACAM6 disrupts tissue architecture and blocks colonocyte differentiation.

Authors:  Christian Ilantzis; Luisa DeMarte; Robert A Screaton; Clifford P Stanners
Journal:  Neoplasia       Date:  2002 Mar-Apr       Impact factor: 5.715

2.  Interphase fluorescence in situ hybridization improves the detection of malignant cells in effusions from breast cancer patients.

Authors:  N Zojer; M Fiegl; J Angerler; L Müllauer; A Gsur; S Roka; M Pecherstorfer; H Huber; J Drach
Journal:  Br J Cancer       Date:  1997       Impact factor: 7.640

3.  Diagnostic value of E-cadherin and fibronectin in differentiation between reactive mesothelial and adenocarcinoma cells in serous effusions.

Authors:  Noushin Afshar Moghaddam; Reza Tahririan; Mehdi Eftekhari; Dana Tahririan; Alireza Rahmani
Journal:  Adv Biomed Res       Date:  2012-08-28
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.